Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine

##plugins.themes.bootstrap3.article.main##

##plugins.themes.bootstrap3.article.sidebar##

Published Jul 28, 2021
DOI: https://doi.org/10.22551/2021.31.0802.10182
Katherine M. Cooper Bradley Switzer

Abstract

Immune thrombocytopenic purpura (ITP) is a rare hematologic condition through to affect 3.3 in 100,000 adults per year in the United States. Many cases of immune thrombocytopenia are diagnosed incidentally with laboratory tests that reveal low platelet count, without a clear cause. However, when platelet counts are very low, patients may show signs of bleeding. Here we present the case of a 24-year-old female with mucocutaneous bleeding ten days after receiving her first dose of SARS-CoV-2 vaccine, who was subsequently found to have severe thrombocytopenia. Extensive work up for new thrombocytopenia was unremarkable suggesting a diagnosis of ITP, potentially secondary to vaccination. Empiric treatment with glucocorticoids was initiated without response prompting the use of intravenous immunoglobulin G.  The patient was discharged on hospital day five with a platelet count over 20,000 platelets per microliter.  In summary, ITP is a potential sequela of the SARS-CoV-2 vaccine, and otherwise healthy young individuals may be at risk for hematologic side effects.

##plugins.themes.bootstrap3.article.details##

Keywords

Coronavirus vaccine, thrombocytopenia, immune reactions

References
1. Zufferey A, Kapur R, Semple JW. Pathogenesis and therapeutic mechanisms in immune thrombocytopenia (ITP). J Clin Med 2017; 6(2):16.
2. Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenia in children and adults: A critical review of published reports. Am J Hematol 2010; 85(3):174-180.
3. Abrahamson PE, Hall SA, Feudjo‐Tepie M, Mitrani‐Gold FS, Logie J. The incidence of idiopathic thrombocytopenic purpura among adults: a population‐based study and literature review. Eur J Haematol 2009; 83(2):83-89.
4. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010; 115(2):168-186.
5. Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005;106(7):2244-2251.
6. ITP A. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120(1):574-596.
7. Lee EJ, Cines DB, Gernsheimer T, et al. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination. Am J Hematol 2021; 96(5):534-537 doi: 10.1002/ajh.26132. Epub 2021 Mar 9.
8. Choi HS, Ji MH, Kim SJ, Ahn HS. Platelet count recovery after intravenous immunoglobulin predicts a favorable outcome in children with immune thrombocytopenia. Blood res 2016; 51(2):95.
9. Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res 2015; 100:190-209.
10. Perricone C, Ceccarelli F, Nesher G, et al. Immune thrombocytopenia (ITP) associated with vaccinations: a review of reported cases. Immunol Res 2014; 60(2-3):226-235.
11. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020; 383(27):2603-2615.
12. Tarawneh O, Tarawneh H. Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine. Am J Hematol 2021; 96(5):E133-E134. doi: 10.1002/ajh.26106.
How to Cite
Cooper, K. M., & Switzer, B. (2021). Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine. Archive of Clinical Cases, 8(2), Arch Clin Cases 2021; 8(2):31-36. https://doi.org/10.22551/2021.31.0802.10182
Issue
Vol. 8 No. 2 (2021)
Section
Case Reports

Archive of Clinical Cases is protected by copyright and may be used in accordance with copyright and other applicable laws. Content available at www.clinicalcases.eu and our digital applications is intended for personal noncommercial use.

Authors who submit a manuscript for publication in Archive of Clinical Cases agree to the following terms: a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) only after the final version of the manuscript was accepted and published, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access). d. It is compulsory that before submission authors ensure that their work was not published in any other medical journals or pending acceptance for publication and that "Archives of Clinical Cases" is the only beneficiary at that moment if their work/case will be accepted by us.

Guidelines for linking to www.clinicalcases.eu a. The main purpose of the site linking to the Archive of Clinical Casess site should be educational. b. Links should be made to the Archive of Clinical Casess home page (www.clinicalcases.eu) or to the articles abstract. c. It is forbidden to use the Archive of Clinical Casess cover by outside organizations unless permission has been granted in advance, notifying our Secretary. d. Material owned by the Archive of Clinical Cases (including the name, logo, cover, and text) may not be used in any manner that may induce the idea or suggest that the Archive of Clinical Cases is in some way recommending a specific company, product or service. e. You must not use or allow others to access or use, all or any part of our Site or the contents and/or applications on it for commercial purposes without our permission. To seek permission to do anything prohibited by or not contained in these TERMS, or which requires our prior consent or agreement, you can contact us.

How to Cite

Cooper, K. M., & Switzer, B. (2021). Severe immune thrombocytopenic purpura after SARS-CoV-2 vaccine. Archive of Clinical Cases, 8(2), Arch Clin Cases 2021; 8(2):31-36. https://doi.org/10.22551/2021.31.0802.10182